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ABSTRACT 
Background: In its 1997 Guideline for Diagnosis and Treatment of Hyper- 
lipidemia in Japanese Adults and subsequent revisions, the Japan Athero- 
sclerosis Society (JAS) recommends erum lipid management goals (SLMGs) 
based on a coronary heart disease (CHD) risk classification. A literature search 
revealed that the status of lipid-lowering therapy based on the current JAS rec- 
ommendations in Japan has not been assessed. 
Objective: The aim of this study was to evaluate the efficacy of current lipid- 
lowering regimens, and to provide the best possible therapeutic strategies for 
patients with hyperlipidemia by identifying risk factors for the development of
CHD, based on the current JAS recommendations. 
Methods: This multicenter, etrospective study was conducted using data 
from patients under the care of physicians at 12,500 randomly selected insti- 
tutions across Japan. Physicians received a survey concerning lipid-lowering 
therapy, on which each physician provided data from 10 consecutive adult 
patients with hyperlipidemia who had been prescribed lipid-lowering ther- 
apy for at least 3 months before the survey was administered, and who were 
undergoing routine follow-up on an outpatient basis. Physicians provided 
patients' demographic and clinical data, including JAS-defined CHD risk clas- 
sification, coronary risk factors and pre- and posttreatment (after _>3 months) 
serum lipid levels, and the types and dosages of drugs in patients' current and 
prior treatment regimens. These data were used to assess the efficacy of lipid- 
lowering regimens and rates of patients achieving the SLMGs recommended 
by the JAS. 
*The J-LAP Investigators included 2540 physicians from 12,500 institutions across Japan. 
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Results: A total of 2540 physicians participated in the survey, and data from 
24,893 Japanese patients (mean [SD] age, 65.8 [10.5] years) with hyperlipidemia 
were included in the study. Patients with familial hyperlipidemia (845/24,893 
[3.4%]) were excluded from most of the analyses, leaving 24,048 patients with 
primary hyperlipidemia. The most prevalent coronary risk factors included age 
(21,902 [91.1%]), hypertension (14,275 [59.4%]), diabetes mellitus type 2 and/or 
impaired glucose tolerance (6346 [26.4%]), and smoking (3841 [16.0%]). A total 
of 20,948 patients (87.1%) had a CHD risk classification of B (ie, >-1 coronary risk 
factor but no history of CHD). At the time of the survey, the lipid-lowering regi- 
mens of 22,080 patients (91.8%) included a statin. The rates of achievement of
SLMGs were as follows: total cholesterol (TC), 12,659/23,840 patients (53.1%); 
low-density lipoprotein cholesterol (LDL-C), 14,025/22,121 (63.4%); high-density 
lipoprotein cholesterol, 19,702/21,279 ( 2.6%); and triglycerides (TG), 14,892/ 
23,569 (63.2%). TC and LDL-C goals were achieved by most patients (>-61.1%) in 
risk categories A, B1, and B2 (ie, 0-2 coronary risk factors; low to moderate 
risk) but by a low percentage of patients (<45.4%) in risk categories B3, B4, and 
C (ie, ---3 coronary risk factors or history of CHD; high risk). In the high-risk 
group (n = 10,515), the TC goal was achieved by 4059 patients (38.6%). The TC 
and LDL-C goals were achieved by significantly higher percentages of patients 
prescribed atorvastatin (5133/7928 [64.7%] and 5487/7426 [73.9%], respectively) 
compared with the rates of patients prescribed any other statin at the recom- 
mended starting doses (all, P < 0.05). 
Conclusions: The results of this study of Japanese patients undergoing lipid- 
lowering therapy for the prevention of CHD, prescribed based on the recom- 
mendations in the JAS guideline, suggest insufficient reduction of TC, LDL-C, 
and TG in patients at high risk for CHD and the need for more aggressive 
lipid-lowering therapy in such patients. (Curr Ther Res Clin Exp. 2005;66:80-95) 
Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Important risk factors for coronary heart disease (CHD) include hypercholes- 
terolemia (total cholesterol [TC], ___220 mg/dL; low-density lipoprotein choles- 
terol [LDL-C], >-140 mg/dL), hypertension (systolic blood pressure/diastolic 
blood pressure, >-160/_>95 mm Hg), age (men, >45 years; women, >55 years), dia- 
betes mellitus type 2 (DM-2) (fasting plasma glucose level, >_126 mg/dL) and/or 
impaired glucose tolerance (IGT) (plasma glucose level on glucose tolerance 
test, >-140 and <200 mg/dL), smoking, a family history of CHD, depressed serum 
high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL), obesity (body mass 
index, >-25 kg/m2), a history of cerebral infarction or arteriosclerosis obliterans 
(ASO), and a history of CHD. Major epidemiologic studies have established a sta- 
tistical correlation between hypercholesterolemia andincreased risk for CHD. 1,2 
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The correlation between hypercholesterolemia andrisk for CHD has also been 
demonstrated bythe finding that decreased levels of serum TC and LDL-C lead 
to CHD risk reduction. 3,4 
The Japan Lipid Intervention Trial (J-LIT) 5 studied a cohort of >50,000 pa- 
tients with hypercholesterolemia prescribed lipid-lowering therapy with sim- 
vastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin), for 
6 years (mean) for the primary prevention of CHD. J-LIT found a higher CHD 
risk when the mean TC concentration was ->240 mg/dL and the mean LDL-C 
concentration was ---160 mg/dL. 5,6 Based on the findings in J-LIT, the Japan 
Atherosclerosis Society (JAS) revised its Guideline for Diagnosis and Treatment 
of hyperlipidemia n Japanese Adults, 7,8 and in 2004 proposed the following 
CHD risk categories based on the number of CHD risk factors present, as fol- 
lows: 0 risk factors, category A; 1, 2, 3, or >_4 risk factors, category B1, B2, B3, or 
B4, respectively; and history of CHD, category C (Table I). 9 Categories A to B2 
are considered low to moderate risk; categories B3 to C are considered high 
risk. The guideline also proposes a strict regimen to achieve serum lipid man- 
agement goals (SLMGs) in patients at high risk. 
Despite the JAS recommendations, in Japan there is insufficient consensus 
among physicians as to the choice of first-line therapy in patients with hyper- 
lipidemia. A study undertaken based on the 1997 guideline 7 found that conven- 
tional therapy using lipid-lowering drugs resulted in insufficient achievements 
of SLMGs.10 However, the guideline revisions 8,9 added a more intensive therapeu- 
tic strategy for the prevention of CHD in patients with hyperlipidemia and mul- 
tiple risk factors, and has been accepted by general practitioners, but to date 
no studies of lipid-lowering therapy based on the revisions have been conduct- 
ed. This study aimed to evaluate the efficacy of current lipid-lowering regimens, 
and to provide the best possible therapeutic strategies for patients with hyper- 
lipidemia by identifying risk factors for the development of CHD, based on the 
current JAS recommendations. 
MATERIALS AND METHODS 
Survey Participants 
This multicenter, retrospective study was conducted using data from 
patients under the care of physicians at 12,500 randomly selected centers 
across Japan. Between January and April 2003, physicians were sent an invita- 
tion to participate in a survey concerning lipid-lowering therapy. Physicians 
who returned the invitation were sent the survey by mail. 
Study Population 
Each physician recruited 10 consecutive patients aged ->18 years with hyper- 
lipidemia (TC, _>220 mg/dL; triglycerides [TG], 2150 mg/dL) who were prescribed 
lipid-lowering therapy for at least 3 months before the survey was administered, 
and who were undergoing routine follow-up on an outpatient basis. 
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Patient data were excluded from the study if patients had a history of severe 
traumatic injury, severe infectious disease, or major surgery within 12 months 
before the survey was administered. 
Methods 
Data from a subgroup of pat ients who were switched to a statin from 
another  drug, including a statin differing from the one originally prescr ibed,  
were analyzed to determine the effects of statins as second-l ine therapy. 
Because the Third Report  of the National Cholesterol  Educational Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol  in Adults (Adult Treatment  Panel III) (NCEP ATP III) 11 indicates 
that pat ients with familial hyper l ip idemia (FH) are resistant to the effects 
of most  cholesterol- lowering medicat ions,  including statins, due to a lack 
of LDL-receptor activity, 11 pat ients with FH were included in a separate  
subanalysis.  
Physic ians provided patients'  demographic  and clinical data, including 
coronary  risk factors, from patients'  files. Patients were assigned a CHD risk 
category  based on the JAS recommendat ions  (Table I), which defines patients 
with hyper l ip idemia but no h istory  of CHD and no coronary  risk factors as 
category  A, and those with no h istory  of CHD but z l  other  risk factor, not 
including elevated LDL-C level, as category  B. Category B is subcategor ized 
as B1 to B4, corresponding to the number  of coronary  risk factors present.  
Patients with DM-2 and/or  IGT are categor ized as B3 risk equivalent,  even if 
no other  risk factors are present  (similar to the CHD risk in the NCEP ATP 
IIIll). Pat ients with a h is tory  of cerebral  infarction or ASO are categor ized as 
B4 or C risk equivalent. Those with a h is tory  of CHD are classified as catego- 
ry C for secondary  prevention.  Similar to the NCEP ATP IIl, 11 the JAS guideline 
uses CHD risk classification, as well as serum lipid levels, to determine therapy  
intensity. 
Data regarding the types and dosages of patients'  current  l ipid-lowering 
regimens, as well as regimens prescr ibed just before the current  one, if any, 
were also col lected. Patients'  current  serum lipid levels and those measured 
just before the switch to the current  regimen, if any, were noted. LDL-C was 
calculated using the Friedewald formula, 12 as follows: 
LDL-C = TC - HDL-C - (TG/5), 
where TG is the serum tr iglyceride level. When this formula could not be 
appl ied due to missing data, we used LDL-C levels from direct homogeneous  
assay. 
Statistical Analysis 
The significance of multiple pairwise comparisons was determined using 
the Student's t test. A P value <0.05 was considered statistically significant. Data 
are expressed as mean (SD). 
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RESULTS 
Study Population 
Demographic and Clinical Characteristics 
Data from 25,261 patients were collected from 2540 physicians across Japan. 
Data from 368 of these patients were excluded for various reasons (eg, data con- 
cerning drug prescribed, lipid levels unavailable), bringing the number of study 
patients to 24,893 (17,184 women, 7709 men; mean [SD] age, 65.8 [10.5] years; 
mean [SD] height, 155.3 [8.8] cm; mean [SD] body weight, 58.6 [10.9] kg; mean 
[SD] body mass index, 24.2 [3.4] kg/m2). Eight hundred forty-five patients (3.4%; 
584 women, 261 men) had FH. 
Coronary Risk Factors and Risk Classification 
Figure 1 shows the prevalence of coronary risk factors in the 24,048 patients 
with primary hyperlipidemia. The most prevalent risk factor was age (21,902 pa- 
tients [91.1%]), followed by hypertension (14,275 [59.4%]), DM-2 and/or IGT 
(6346 [26.4%]), smoking (3841 [16.0%]), history of CHD (2319 [9.6%]), and de- 
pressed HDL-C level (2196 [9.1%]). 
When the 24,048 patients with primary hyperlipidemia were classified based on 
coronary risk factors according to the JAS 2002 guideline, 8 781 (3.2%) were classi- 
fied as category A, 5419 (22.5%) as B1, 7219 (30.0%) as B2, 5667 (23.6%) as B3, 2643 
(11.0%) as B4, and 2319 (9.6%) as C. Thus, 20,948 patients (87.1%) were classified 
as category B, 18,305 (87.4%) of whom were classified as B1 to B3 (Figure 2). 
Of the patients in category B3 (n = 5667), 1696 (29.9%) had 3 coronary risk 
factors other than DM-2 and/or IGT, and 3971 (70.1%) had DM-2 and/or IGT (ie, 
B3 risk equivalent). Of the patients in category B4 (n = 2643), 1132 (42.8%) had 
3 or 4 risk factors plus DM-2 and/or IGT, 897 (33.9%) had a history of cerebral 
infarction or ASO (ie, B4 risk equivalent), 474 (17.9%) had DM-2 and/or IGT in 
addition to a history of cerebral infarction or ASO, and 235 (8.9%) had >__4 risk 
factors other than DM-2 and/or IGT. 
Therapy Prescribed 
At the time of the survey, 22,080 patients (91.8%) were prescribed a combi- 
nation therapy regimen that included a statin. Of these, 21,138 (95.7%) were pre- 
scribed statin monotherapy. Of these 21,138 patients, 7996 (37.8%) were pre- 
scribed atorvastatin, 7592 (35.9%) pravastatin, 3536 (16.7%) simvastatin, and 
2014 (9.5%) fluvastatin. A total of 21,221 of these 22,080 patients (96.1%) were 
prescribed the starting dose of these drugs, as follows: atorvastatin 10 mg/d 
(7852 patients [37.0%]), pravastatin 10 mg/d (7640 [36.0%]), simvastatin 5 mg/d 
(3607 [ 17.0% ]), and fluvastatin 20 mg/d (2122 [ 10.0 % ]). Only 740 patients (3.5 %) 
were prescribed an up-titrated ose of a statin (data not shown). 
Serum Lipid Levels 
Mean (SD) serum lipid levels after >3 months of treatment in the patients 
with primary hyperlipidemia (n = 24,048) were as follows: TC, 208.6 (31.3) mg/dL 
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Age* 
Hypertension 
DM-2 and/or IGT 
Smoking 
History of CHD 
Depressed HDL-C Level _ 
History of Stroke 
Family History of CHD 
History of ASO 
I I  
II 
0 20 40 60 80 100 
Patients (%) 
Figure 1. Distribution of study patients across coronary risk factors (n -- 24,048; 
data from patients with familial hyperlipidemia are not included). DM-2 = 
diabetes mellitus type 2; IGT = impaired glucose tolerance; CHD -- coronary 
heart disease; HDL-C -- high-density lipoprotein cholesterol; ASO -- arterio- 
sclerosis obliterans. *Men, >45 years; women, ->55 years. 
• B1 
[ ]  B2 
[ ]  B3 
[ ]  B4 
F~c 
Figure 2. Distribution of study patients across coronary heart disease risk categories 
defined in a revision of the Japan Atherosclerosis Society Guideline for 
Diagnosis and Treatment of Hyperlipidemia in Japanese Adults 9 (n = 24,048; 
data from patients with familial hyperlipidemia are not included). See Table | 
for definitions of risk categories. 
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(n =- 23,840); LDL-C, 122.1 (37.1) mg/dL (n -- 22,121); HDL-C, 59.4 (17.2) mg/dL 
(n : 21,279); and TG, 147.8 (97.4) mg/dL (n = 23,569). The rates of achieve- 
ment of SLMGs were as follows: TC, 12,659/23,840 patients (53.1%); LDL-C, 
14,025/22,121 (63.4%); HDL-C, 19,702/21,279 ( 2.6%); and TG, 14,892/23,569 (63.2%). 
When serum levels of TC (Figure 3A) and LDL-C (Figure 313) were distributed 
by CHD risk category, they were nearly identical. 
Efficacy of Starting Doses of Statins 
Used as Second-Line Therapy 
Of 7102 patients prescribed a statin as second-line therapy, 1044 (14.7%) 
were switched from a previous therapy not containing a statin, 5965 (84.0%) 
from another statin, 672 (9.5%) from a fibrate, 372 (5.2%) from other drugs, and 
93 (1.3%) from unknown drugs. 
The effects of second-line treatment with a statin at the starting dose on 
serum lipid levels and the rates of achieving SLMGs with this drug class are 
shown in Table II. Treatment with atorvastatin or simvastatin was associated 
with significant reductions in mean serum TC, LDL-C, and TG levels (changes, 
-19.3%, -27.5%, and -18.7%, respectively) (all, P < 0.05). The rates of achieving 
TC and LDL-C goals were significantly greater with atorvastatin (2571/4167 
[61.7%] and 2586/3586 [72.1%], respectively) compared with simvastatin (309/ 
682 [45.3%] and 339/575 [59.0%], respectively) (both, P < 0.05). The 7102 pa- 
tients prescribed a statin as second-line therapy experienced significant 
decreases in TC, LDL-C, and TG (changes, -14.7%, -21.0%, and -17.5%, respec- 
tively) (all, P < 0.05) and a significant increase in HDL-C (1.0%; P < 0.05). 
Moreover, the rates of achieving SLMGs significantly increased after the pre- 
scription change for TC (from 17.4% to 54.5%), LDL-C (from 27.2% to 65.0%), and 
TG (from 50.3% to 61.6%) (all, P < 0.05) (data not shown). 
TC goals were achieved in 541/706 patients (76.6%) in category A, 3040/4944 
(61.5%) in B1, 4232/6380 (66.3%) in B2, 1957/4803 (40.7%) in B3, 972/2132 
(45.6%) in B4, and 544/1985 (27.4%) in C. LDL-C goals were achieved by 600/688 
(87.2%) of patients in category A, 3485/4669 (74.6%) in B1, 4639/5964 (77.8%) in 
B2, 2283/4441 (51.4%) in B3, 1059/1950 (54.3%) in B4, and 559/1814 (30.8%) in C. 
The rates of achieving TC and LDL-C goals were significantly higher in pa- 
tients prescribed atorvastatin (5133/7928 patients [64.7%] and 5487/7426 pa- 
tients [73.9%], respectively) compared with simvastatin (1788/3490 [51.2%] and 
2072/3277 [63.2%], respectively), fluvastatin (954/2002 [47.7%] and 1081/1855 
[58.3%], respectively), and pravastatin (3411/7530 [45.3%] and 3985/6968 [57.2%], 
respectively) (all, P < 0.05) (Figure 4). 
When rates of achievement of TC (Figure 5A) and LDL-C (Figure 513) goals 
were distributed by CHD risk category, patients who were prescribed atorva- 
statin had the highest rates (TC, 5133/7928 patients [64.7%]; LDL-C, 5487/7426 
[73.9%]). The mean rate of achieving the HDL-C goals by statins across risk cate- 
gories was 92.6%; the mean rate of achieving the TG goals by statins across all 
risk categories was 63.2% (data not shown). 
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Figure 3. Distribution of serum levels of total cholesterol (TC) (A) and low-density 
l ipoprotein cholesterol (LDL-C) (B) by coronary heart disease (CHD) risk 
category in patients with hyperl ipidemia prescribed l ipid-lowering therapy 
based on recommendations in a revision of the Japan Atherosclerosis 
Society (JAS) Guideline for Diagnosis and Treatment of Hyperl ipidemia in 
Japanese Adults 9 (TC, n = 23,840; LDL-C, n = 22,121). The serum lipid man- 
agement goal (SLMG) for each CHD risk category as recommended by the 
JAS is shown. See Table I for definit ions of CHD risk categories. 
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Table II. Serum lipid concentrations and achievement rates of serum lipid management 
goals (SLMGs)* before and after ->3 months of second-line lipid-lowering treat- 
ment with a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) at 
the starting dose in patients with primary hyperlipidemia (n -- 22,080). 
Serum Lipid Concentration, 
Mean (SD), mg/dL 
SLMG Achievement Rate, 
No. (%) 
No. of 
Statin/Lipid Patients Before After Before After 
Atorvastatin 
TC 4167 251.4 (35.1) 202.8 (32.0) t 429 (10.3) 2571 (61.7)* 
LDL-C 3586 158.8 (42.9) 115.2 (33.3) t 746 (20.8) 2586 (72.1)* 
TG 4035 183.1 (130.1) 148.9 (89.6) t§ 1941 (48.1) 2498 (61.9) 
Pravastatin 
TC 923 229.2 (40.1) 215.3 (29.3) t 289 (31.3) 395 (42.8) 
LDL-C 770 142.4 (42.6) 128.9 (29.2) t 305 (39.6) 412 (53.5) 
TG 892 156.2 (121.8) 150.0 (111.8) 553 (62.0) 553 (62.0) 
Simvastatin 
TC 682 238.5 (36.4) 21 3.6 (29.6) t 1 37 (20.1) 309 (45.3) 
LDL-C 575 149.1 (35.5) 125.3 (27.2) t 170 (29.6) 339 (59.0) 
TG 659 165.1 (1 32.4) 147.9 (91.5) t§ 394 (59.8) 408 (61.9) 
Fluvastatin 
TC 464 231.9 (36.1) 21 7.7 (28.4) t 118 (25.4) 190 (41.0) 
LDL-C 393 143.7 (34.4) 1 31.2 (39.5) t 135 (34.4) 1 99 (50.6) 
TG 449 150.1 (80.7) 144.4 (93.7) 262 (58.4) 285 (63.5) 
TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides. 
*See Table I for SLMGs. 
tp < 0.05 versus before treatment. 
$P < 0.05 versus simvastatin. 
§P < 0.05 versus pravastatin and fluvastatin. 
Therapies Administered to Patients 
w i th  Familial Hyperl ip idemia 
Of the 845 patients (3.4%) with FH, 693 (82.0%) were prescribed monother- 
apy with a statin. Of those patients, 344 (49.6%) were prescribed atorva- 
statin, 183 (26.4%) pravastatin, 107 (15.4%) simvastatin, and 59 (8.5%) fluva- 
statin. The majority of patients (9723 [40.4%]) were prescribed the starting 
dose of the statin, although 686 (2.9%) were prescribed a higher dose. Mean 
(SD) serum lipid levels posttreatment i  he patients with FH were as follows: 
TC, 227.2 (40.3) mg/dL (n = 833); LDL-C, 140.1 (59.1) mg/dL (n = 776); HDL-C, 
58.6 (17.0) mg/dL (n = 768); and TG, 160.0 (143.3) mg/dL (n = 832). Using cate- 
gory C SLMGs, the TC goal was achieved by 72/833 patients (8.6%), LDL-C by 
102/776 (13.1%), HDL-C by 700/768 (91.1%), and TG by 508/832 (61.1%) (data 
not shown). 
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Figure 4. Rates of achievement of serum total cholesterol (TC) (n -- 22,908) and low- 
density lipoprotein cholesterol (LDL-C) (n = 21,273) management goals af- 
ter ->3 months of lipid-lowering monotherapy at starting doses in patients 
with primary hyperlipidemia. *P < 0.05 versus all other treatments. 
DISCUSSION 
Clinical research in Japan and elsewhere has shown that the risk for CHD can 
be reduced by decreasing cholesterol levels. 1-6 Based on these findings, 
SLMGs are included in the treatment guidelines in Japan and elsewhere for the 
prevention of CHD. However, rates of achieving SLMGs have been shown to 
be unsatisfactory worldwide. For example, the Lipid Treatment Assessment 
Project, 13 a US survey, found that 38% of patients achieved the LDL-C goals 
recommended in NCEP ATP II. ]4 Thirty-six percent of patients in the Belgian/ 
Luxembourg Survey on Achievement of European Atherosclerosis Society 
Lipid Goals ]5 achieved LDL-C goals in the Recommendation f the European 
Atherosclerosis Society. 16 
Administering statin-based lipid-lowering therapy to persons irrespective of 
their initial cholesterol concentrations or hypertensive patients at high risk for 
CHD significantly reduces the risk for CHD and myocardial infarction. 17,]8 Stat- 
ins exhibit pleiotropic effects (including anti-inflammatory and antioxidative ef- 
fects) ]9 that are thought o increase the usefulness of statin-based lipid-lowering 
therapies for the prevention of CHD. 
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Figure 5. Rates of achievement of serum total cholesterol (TC) (n = 23,840) (A) and 
low-density l ipoprotein cholesterol (LDL-C) (n -- 22,121) (B) management  
goals by coronary heart disease (CHD) risk category after >3 months of 
l ip id- lower ing monotherapy w i th  the starting doses of statins in patients 
w i th  hyperl ipidemia. See Table I for def init ions of risk categories. 
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In the present study, the distribution of patients across Japan corresponded 
closely to the by-prefecture population distribution i  Japan. Thus, the data col- 
lected are thought o allow a proper assessment of nationwide therapy status. 
This survey included a large number of elderly patients (aged >65 years) and 
women (whose CHD risk is higher than that of men8). Clinical studies reported 
after the first guideline 7 was published have demonstrated the efficacy of lipid- 
lowering therapy in the elderly. 2°,21 J-LIT 5 focused on both the elderly aged 65 
to 70 years and aged <64 years with TC levels >270 mg/dL on enrollment. This 
trial showed that TC levels decreased to ___270 mg/dL during follow-up and LDL-C 
levels decreased to ___130 mg/dL (from _>180 mg/dL at baseline), with lipid-lowering 
drugs. The absolute reduction in patients aged 65 to 70 years was similar to that 
in patients aged ___64 years. 5Thus, patients aged _>65 years were included in the 
present study. 
We found that 87.1% of patients prescribed lipid-lowering therapy were clas- 
sified as category B, with most of those patients failing into categories B1 to B3. 
The JAS classifies patients with DM-2 and/or IGT, which is considered a coro- 
nary risk factor, as B3 risk equivalent. A total of 70.1% of the patients in catego- 
ry B3 had DM-2 and/or IGT in addition to other risk factors, whereas 2.7% of 
patients had DM-2 and/or IGT as the sole risk factor. The stratification of pa- 
tients by detailed risk categories might help health care professionals produce 
optimal risk-reduction programs for the prevention of CHD. 
The rates of achieving the TC and LDL-C goals (53.1% and 63.4%, respective- 
ly) are not satisfactory because successful attainment of NCEP goals u ranges 
from 40% to 50%. 14 In contrast, the rate of achieving the HDL-C goal (92.6%) was 
satisfactory based on NCEP attainment goals, n Although the LDL-C goals rec- 
ommended in JAS 20028 are comparable to those in NCEP ATP III, u the JAS pro- 
vides more detailed risk categories based on lipid levels (Table I). Briefly, 
NCEP ATP III u recommends LDL-C-lowering therapy for the primary prevention 
of CHD based on the Framingham CHD Risk Assessment Tool 22-24 and a CHD risk 
classification that uses just 2 categories: ~ 1 coronary risk factor (low to moderate) 
and _>2 coronary risk factors (high). Although both guidelines were developed 
for clinicians managing patients with elevated LDL-C levels, the JAS provides 
criteria for achieving LDL-C goals using more intensive drug therapy based on 
more CHD risk categories. 9 
In the present study, TC goals were achieved by -60% to 80% of patients in 
categories A, B1, and B2; LDL-C goals were achieved by -70% to 90% of patients 
in these categories. However, in patients in categories B3 to C, the rates were 
unsatisfactory: 27.4% of patients in category C achieved the TC goals. These 
findings suggest he need for more aggressive lipid-lowering therapy for pa- 
tients at high coronary risk. 
The mean serum TC and LDL-C levels were statistically similar in patients 
in all CHD risk categories (TC, -210 mg/dL; LDL-C, 120 mg/dL). Few patients 
in category C were prescribed high doses of a statin even though many failed 
to achieve the SLMGs. This finding suggests that physicians in the present 
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study might have prescribed therapy based on JAS 1997, 7 in which the TC 
goal was <220 mg/dL. Although it is essential to prescribe lipid-lowering ther- 
apy based on the pathology in the individual patient, it is hoped that patients 
at high risk for CHD are treated according to the current JAS recommen- 
dations, 8,9 in which more intensive therapy is recommended to achieve the 
SLMGs. 
The present study suggests that the statins as second-line therapy are effec- 
tive in normalizing TC and LDL-C levels. Compared with the other statins, ator- 
vastatin and simvastatin were associated with greater eductions in TG level 
(Table II) (both, P < 0.05 vs pravastatin and fluvastatin). Overall, patients pre- 
scribed atorvastatin had the highest SLMG achievement rates. Based on the 
fact that all of the drugs were prescribed at their starting doses, it might be 
concluded that the effectiveness of atorvastatin is not dose dependent but 
rather is attributable to its innate action. However, it should be noted that, 
because up-titration of the other drugs is ineffective, physicians might not be 
prescribing the appropriate doses. In the present study, treatment was up- 
titrated in 3.5% of patients. Based on this finding, if a physician prescribes 
drugs at their starting doses, treatment success is more likely to be expected. 
Switching from a nonstatin to a statin or from one statin to another (14.7% or 
84.0% of the total population, respectively) was associated with improved lipid 
levels and increased achievement rates, which prompted the JAS recommenda- 
tion to switch patients not achieving their goals to another therapeutic drug. 
Patients with FH (3.4% of the study population) were not prescribed a high- 
er mean dose of any drug than patients with primary hyperlipidemia. Rates of 
achieving TC and LDL-C goals based on category C standards were both low-- 
-10%--suggesting a need to treat patients with FH more aggressively. 
CONCLUSIONS 
The results of this study of Japanese patients undergoing lipid-lowering therapy 
for the prevention of CHD, prescribed based on the JAS recommendations, sug- 
gest insufficient reduction of TC, LDL-C, and TG in patients at high risk for CHD 
and the need for more aggressive lipid-lowering therapy in such patients. 
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